Abcam, ab266320, Human STT3A knockout HEK-293T cell line

Size: 1000000Cells / vial / 2 x 1000000Cells / vial
STT3A KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 10. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 10

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-STT3A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
STT3A also known as oligosaccharyltransferase 48 kDa subunit plays an important role in the enzymatic process of N-glycosylation specifically as a catalytic subunit in the oligosaccharyltransferase (OST) complex. This protein has a mass of approximately 48 kDa. STT3A is expressed predominantly in rough endoplasmic reticulum membranes where it contributes to the transfer of oligosaccharides onto nascent polypeptide chains a critical step for protein maturation and function.
Biological function summary
STT3A is part of the OST complex which catalyzes the transfer of glycan from a lipid donor to asparagine residues on nascent polypeptides in a process known as co-translational N-glycosylation. This modification is essential for proper protein folding stability and activity. The OST complex with STT3A as a catalytic core is fundamental in eukaryotic cells affecting the function of numerous glycoproteins. It interacts with various components within the endoplasmic reticulum to ensure efficient glycosylation.
Pathways
The involvement of STT3A extends to the protein processing in endoplasmic reticulum pathway and is integral to the broader process of protein folding and quality control. This pathway ensures proper protein configuration and prevents the accumulation of misfolded proteins. STT3A functionally relates to proteins like calnexin and calreticulin which work in the calnexin/calreticulin cycle to assist in the folding of glycoproteins indicating its important role in maintaining protein homeostasis in cells.
Defects or dysregulation of STT3A have associations with congenital disorders of glycosylation (CDG) a group of rare inherited metabolic disorders affecting glycoprotein synthesis. Anomalies in STT3A activity can disrupt normal glycoprotein functions leading to a wide range of symptoms including developmental delays and neurological issues. Moreover STT3A dysfunction has connections with cancer progression as altered N-glycosylation patterns are frequently observed in tumor cells affecting proteins such as EGFR and HER2 which are often targets in oncogenesis.